DIAGNOSTIC PRODUCTS CORP
10-Q, EX-27, 2000-08-11
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: DIAGNOSTIC PRODUCTS CORP, 10-Q, 2000-08-11
Next: FIDELITY ADVISOR SERIES III, 13F-NT, 2000-08-11



<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                           8,897
<SECURITIES>                                         0
<RECEIVABLES>                                   68,994
<ALLOWANCES>                                       769
<INVENTORY>                                     58,366
<CURRENT-ASSETS>                               139,773
<PP&E>                                         112,458
<DEPRECIATION>                                  58,603
<TOTAL-ASSETS>                                 259,569
<CURRENT-LIABILITIES>                           44,816
<BONDS>                                              0
                                0
                                          0
<COMMON>                                        39,639
<OTHER-SE>                                     175,114
<TOTAL-LIABILITY-AND-EQUITY>                   259,569
<SALES>                                        122,829
<TOTAL-REVENUES>                               122,829
<CGS>                                           55,154
<TOTAL-COSTS>                                   55,154
<OTHER-EXPENSES>                                35,705
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                 19,449
<INCOME-TAX>                                     6,129
<INCOME-CONTINUING>                             13,320
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    13,320
<EPS-BASIC>                                       0.97
<EPS-DILUTED>                                     0.96


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission